Treatment of stage III non-small cell lung cancer in the era of immunotherapy: pathological complete response to neoadjuvant pembrolizumab and chemotherapy

Non-small cell lung cancer (NSCLC) accounts for about 85% of all lung cancers. The expected 5-year survival of stage III NSCLC ranges from 13% to 36% for stage III. Due to the heterogeneity and poor efficacy of stage III patients, there is great controversy on how to optimize the therapy strategy. I...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Zhang-Ru, Liu, Mi-Na, Yu, Jia-Hua, Yang, Yun-Hai, Chen, Tian-Xiang, Han, Yu-Chen, Zhu, Lei, Zhao, Ji-Kai, Fu, Xiao-Long, Cai, Xu-Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2020
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7653116/
https://www.ncbi.nlm.nih.gov/pubmed/33209626
http://dx.doi.org/10.21037/tlcr-20-896

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7653116/
https://www.ncbi.nlm.nih.gov/pubmed/33209626
http://dx.doi.org/10.21037/tlcr-20-896

Ejemplares similares